|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Radiofrequency ablation or percutaneous ethanol injection for the treatment of liver tumors显示文摘The liver is a common location of both primary and secondary malignancies. For unresectable liver cancer, many local ablative therapies have been developed. These include e.g., percutaneous ethanol injection (PEI), percutaneous acetic acid injection, radiofrequency ablation (RFA), cryoablation, microwave ablation, laserinduced thermotherapy, and high-intensity focused ultrasound. RFA has recently gained interest and is the most widely applied thermoablative technique. RFA allows more effective tumor control in fewer treatment sessions compared with PEI, but with a higher rate of complications. However, there are certain circumstances where PEI therapy represents a better strategy to control liver tumors than RFA, especially in situations where RFA is difficult, for example when large vessels surround the tumor. In the context of hepatocellular carcinoma (HCC), both RFA and PEI are feasible and of benefit in non-operable patients. RFA seems superior to PEI in HCC > 2 cm, and the combination of interventions may be of benefit in selected patients. Liver resection is superior to RFA for patients with HCC meeting the Milan criteria, but RFA can be employed in tumors ≤ 3 cm and where there is an increased expected operative mortality. In addition, some lines of evidence indicate that RFA and PEI can be employed as a bridge to liver transplantation. The use of RFA in colorectal liver metastases is currently limited to unresectable disease and for patients unfit for surgery. The aim of this article is to summarize the current status of RFA in the management of liver tumors and compare it to the cheap and readily available technique of PEI. | Daniel Ansari Roland Andersson | 2012 | World Journal of Gastroenterology2012，18，10： | 39 |
| 2 | Tissue factor in predicted severe acute pancreatitis显示文摘AIM: To study tissue factor (TF) in acute pancreatitis and evaluate the role of TF as a predictive marker of severity. METHODS: Forty-nine consecutive patients admitted to Lund University Hospital, fulfilling the criteria of predicted severe acute pancreatitis (AP), were recruited prospectively between 2002 and 2004. Blood samples for TF analyses were drawn at inclusion in the study and 12 h, 1 d and 3 d later. RESULTS: Twenty-seven patients developed mild AP, and 22 patients severe AP. At inclusion in the study, the groups were comparable with respect to gender, aetiology, Acute Physiology and Chronic Health Evaluation Ⅱ score, and duration of pain. At inclusion in the study and at 12 h, TF was higher in the severe AP group (P = 0.035 and P = 0.049, respectively). After 1 and 3 d, no differences in TF levels were noted. Interleukin (IL)-6 was significantly higher in the severe AP group at all of the studied time points. C-reactive protein (CRP) was significantly higher in the AP group at 1 and 3 d. In receiver operating characteristic-curves, the area under the curve (AUC) for TF was 0.679 (P = 0.035) at inclusion in the study, and a cut off level for TF of 40 pg/mL showed a sensitivity of 71% and a specificity of 67%, whereas corresponding AUC for IL-6 was 0.775, P = 0.001, and for CRP was 0.653. IL-6 showed better AUC-values than TF at all time points studied. CONCLUSION: TF-levels are raised early in severe AP. TF as an early predictive marker of severe AP is superior to CRP, but inferior to IL-6. | Ellen Andersson Jakob Axelsson Gunilla Eckerwall Daniel Ansari Roland Andersson | 2010 | World Journal of Gastroenterology2010，16，48： | 26 |
| 3 | Update on the management of pancreatic cancer:Surgery is not enough显示文摘Pancreatic ductal adenocarcinoma(PDAC) represents the fourth cause of death in cancer and has a 5-year survival of < 5%.Only about 15% of the patients present with a resectable PDAC with potential to undergo 'curative' surgery.After surgery,local and systemic recurrence,is though very common.The median survival of resected patients with adjuvant chemotherapy after surgery is only 20-23 mo.This underscores the significant need to improve PDAC management strategies.Increased survival rate is dependent on new breakthroughs in our understanding of not at least tumor biology.The aim of this review is to update and comment on recent knowledge concerning PDAC biology and new diagnostics and treatment modalities.One fundamental approach to improve survival rates is by earlier and improved diagnosis of the disease.In recent years,novel blood-based biomarkers have emerged based on genetic,epigenetic and protein changes in PDAC with very promising results.For biomarkers to enter clinical practice they need to have been developed using adequate control groups and provide high sensitivity and specificity and by this identify patients at risk already in a pre-symptomatic stage.Another way to improve outcomes,is by employing neoadjuvant treatments thereby increasing the number of resectable cases.Novel systemic treatment regimes like FOLFIRINOX and nab-paclitaxel have demonstrated improvements in prolonging survival in advanced cases,but long-term survival is still scarce.The future improved understanding of PDAC biology will inevitably render new treatment options directed against both the cancer cells and the surrounding microenvironment. | Daniel Ansari Adam Gustafsson Roland Andersson | 2015 | World Journal of Gastroenterology2015，21，11： | 18 |
| 4 | Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?显示文摘AIM:To assess whether gemcitabine-based combination therapy improves the prognosis of unresectable pancreatic cancer compared with gemcitabine treatment alone.METHODS:A quantitative up-to-date meta-analysis was undertaken to investigate the efficacy of gemcitabine-based combination treatment compared with gemcitabine monotherapy in locally advanced or metastatic pancreatic cancer.Inclusion was limited to highquality randomized clinical trials.RESULTS:Twenty-six studies were included in the present analysis,with a total of 8808 patients recruited.The studies were divided into four subgroups based on the different kinds of cytotoxic agents,including platinum,fluoropyrimidine,camptothecin and targeted agents.Patients treated with gemcitabine monotherapy had significantly lower objective response rate [risk ratio(RR),0.72;95% confidence interval(CI):0.63-0.83;P < 0.001],and lower 1-year overall survival(RR,0.90;95%CI:0.82-0.99;P = 0.04).Gemcitabine monotherapy caused fewer complications,including fewer grade 3-4 toxicities:including vomiting(RR,0.75;95%CI:0.62-0.89;P = 0.001),diarrhea(RR,0.66;95%CI:0.49-0.89;P = 0.006),neutropenia(RR,0.88;95%CI:0.72-1.06;P = 0.18),anemia(RR,0.96;95%CI:0.82-1.12;P = 0.60),and thrombocytopenia(RR,0.76;95%CI:0.60-0.97;P = 0.03) compared with gemcitabine combination therapies.CONCLUSION:Gemcitabine combination therapy provides a modest improvement of survival,but is associated with more toxicity compared with gemcitabine monotherapy. | Chen Sun Daniel Ansari Roland Andersson De-Quan Wu | 2012 | World Journal of Gastroenterology2012，18，35： | 15 |
| 5 | hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review显示文摘High human equilibrative nucleoside transporter 1(hENT1)-expression has shown a survival benefit in pancreatic cancer patients treated with gemcitabine in several studies.The aim of this systematic review was to summarize the results and try to assess the predictive value of hENT1 for determining gemcitabine outcome in pancreatic cancer.Relevant articles were obtained from PubMed,Embase and Cochrane databases.Studies evaluating hENT1-expression in pancreatic tumor cells from patients treated with gemcitabine were selected.Outcome measures were overall survival,disease-free survival(DFS),toxicity and response rate.The database searches identified 10 studies that met the eligibility criteria,and a total of 855 patients were included.Nine of 10 studies showed a statistically significant longer overall survival in univariate analyses in patients with high hENT1-expression compared to those with low expression.In the 7 studies that reported DFS as an outcome measure,6 had statistically longer DFS in the high hENT1 groups.Both toxicity and response rate were reported in only 2 articles and it was therefore hard to draw any major conclusions.This review provides evidence that hENT1 is a predictive marker for pancreatic cancer patients treated with gemcitabine.Some limitations of the review have to be taken into consideration,the majority of the included studies had a retrospective design,and there was no standardized scoring protocol for hENT1-expression. | Stina Nordh Daniel Ansari Roland Andersson | 2014 | World Journal of Gastroenterology2014，20，26： | 7 |
| 6 | Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas显示文摘Pancreatic ductal adenocarcinoma carries a poor prognosis with annual deaths almost matching the reported incidence rates. Surgical resection offers the only potential cure. Yet, even among patients that undergo tumor resection, recurrence rates are high and long-term survival is scarce. Various tumorrelated factors have been identified as predictors of survival after potentially curative resection. These factors include tumor size, lymph node disease, tumor grade, vascular invasion, perineural invasion and surgical resection margin. This article will re-evaluate the importance of these factors based on recent publications on the topic, with potential implications for treatment and outcome in patients with pancreatic cancer. | Daniel Akerberg Daniel Ansari Roland Andersson | 2016 | World Journal of Gastroenterology2016，22，28： | 7 |
| 7 | Pancreatic cancer:Translational research aspects and clinical implications显示文摘Despite improvements in surgical techniques and adjuvant chemotherapy,the overall mortality rates in pancreatic cancer have generally remained relatively unchanged and the 5-year survival rate is actually below 2%.This paper will address the importance of achieving an early diagnosis and identifying markers for prognosis and response to therapy such as genes,proteins,microRNAs or epigenetic modifications.However,there are still major hurdles when translating investigational biomarkers into routine clinical practice.Furthermore,novel ways of secondary screening in high-risk individuals,such as artificial neural networks and modern imaging,will be discussed.Drug resistance is ubiquitous in pancreatic cancer.Several mechanisms of drug resistance have already been revealed,including human equilibrative nucleoside transporter-1 status,multidrug resistance proteins,aberrant signaling pathways,microRNAs,stromal influence,epithelial-mesenchymal transition-type cells and recently the presence of cancer stem cells/cancer-initiating cells.These factors must be considered when developing more customized types of intervention('personalized medicine').In the future,multifunctional nanoparticles that combine a specific targeting agent,an imaging probe,a cell-penetrating agent,a biocompatible polymer and an anticancer drug may become valuable for the management of patients with pancreatic cancer. | Daniel Ansari Bi-Cheng Chen Lei Dong Meng-Tao Zhou Roland Andersson | 2012 | World Journal of Gastroenterology2012，18，13： | 4 |
| 8 | Immune checkpoint therapy for pancreatic cancer显示文摘Novel treatment modalities are necessary for pancreatic cancer. Immunotherapy with immune checkpoint inhibition has shown effect in other solid tumors, and could have a place in pancreatic cancer treatment. Most available clinical studies on immune checkpoint inhibitors for pancreatic cancer are not yet completed and are still recruiting patients. Among the completed trials, there have been findings of a preliminary nature such as delayed disease progression and enhanced overall survival after treatment with immune checkpoint inhibitors in mono- or combination therapy. However, due to small sample sizes, major results are not yet identifiable. The present article provides a clinical overview of immune checkpoint inhibition in pancreatic cancer. Pub Med, Clinical Trials.gov and American Society of Clinical Oncology's meeting abstracts were systematically searched for relevant clinical studies. Four articles, five abstracts and 25 clinical trials were identified and analyzed in detail. | Henrik Johansson Roland Andersson Monika Bauden Sarah Hammes Stefan Holdenrieder Daniel Ansari | 2016 | World Journal of Gastroenterology2016，22，43： | 4 |
| 9 | Proteome-based biomarkers in pancreatic cancer显示文摘Pancreatic cancer,as a highly malignant cancer and the fourth cause of cancer-related death in world,is characterized by dismal prognosis,due to rapid disease progression,highly invasive tumour phenotype,and resistance to chemotherapy.Despite significant advances in treatment of the disease during the past decade,the survival rate is little improved.A contributory factor to the poor outcome is the lack of appropriate sensitive and specific biomarkers for early diagnosis.Furthermore,biomarkers for targeting,directing and assessing therapeutic intervention,as well as for detection of residual or recurrent cancer are also needed.Thus,the identification of adequate biomarkers in pancreatic cancer is of extreme importance.Recently,accompanying the development of proteomic technology and devices,more and more potential biomarkers have appeared and are being reported.In this review,we provide an overview of the role of proteome-based biomarkers in pancreatic cancer,including tissue,serum,juice,urine and cell lines.We also discuss the possible mechanism and prospects in the future.That information hopefully might be helpful for further research in the field. | Chen Sun Ann H Rosendahl Roland Andersson Daniel Ansari | 2011 | World Journal of Gastroenterology2011，17，44： | 3 |
| 10 | Pancreatic cancer – cost for overtreatment with gemcitabine显示文摘 | Daniel Ansari Bobby Tingstedt Roland Andersson | 2013 | Acta Oncologica2013，，6： | 2 |
| 11 | Fast-track surgery: procedure-specific aspects and future direction 显示文摘 | Daniel Ansari Luca Gianotti Jorg Schroder | 2013 | Langenbecks Arcb Surg2013，，： | 1 |
| 12 | The effect of selected hemp seed protein hydrolysates in modulating vascular function显示文摘Reduced bioavailability of nitric oxide along with an increase in inflammatory cytokines,reactive oxygen species,cell adhesion molecules,and platelet hyperactivity are underlying causes of endothelial dysfunction.Bioactive peptides derived from various plants have been shown to attenuate biomarkers of endothelial dysfunction.The objective of this study was to determine the effects of hemp seed protein hydrolysates(HSPH)in modulating biomarkers of endothelial dysfunction using an in vitro cell culture model and an ex vivo platelet activity assay.HUVEC cells were treated with HSPH from commercial variant X and ECO-commercial variant Y,followed by hydrogen peroxide to simulate oxidative stress and inflammation.Biomarkers of endothelial dysfunction were then measured to determine the protective properties of HSPH.Blood samples collected from healthy volunteers were used to determine the effect of the HSPH on ADP and hydrogen peroxide-induced platelet activity,using flow cytometry.The HSPH reduced the production of reactive oxygen species,inflammatory cytokines IL-8,IL-12p70 and IL-1β,and adhesion molecule vascular cell adhesion molecule 1.Additionally,treatment with HSPH also reduced platelet activation marker CD62P ex vivo.The results obtained from this study suggest HSPH alleviates biomarkers of endothelial dysfunction by reducing oxidative stress,inflammation and platelet activation. | Raiyan Mahbub Esther Callcott Shiwangni Rao Omid Ansari Daniel L.E.Waters Christopher L.Blanchard Abishek B.Santhakumar | 2022 | Food Bioscience2022，45，1： | 1 |
| 13 | Chronic pancreatitis: potential future interventions显示文摘 | Daniel Ansari Ellen Andersson Bodil Andersson Roland Andersson | 2010 | Scandinavian Journal of Gastroenterology2010，，9： | 1 |
| 14 | Fast-track surgery: procedure-specific aspects and future direction显示文摘 | Daniel Ansari Luca Gianotti J?rg Schr?der Roland Andersson | 2013 | Langenbeck’s Archives of Surgery2013，，： | 1 |
| 15 | 采用分析方法、毒理学和风险评估研究评估多环芳烃:以石油泄漏后海产品安全为案例显示文摘[背景]多环芳香烃(PAHs)是一种大量蔓延的环境化学物质。它们可通过自然和人为过程产生,通常存在于有机介质(包括石油)中。有几种PAHs是有毒的,其中一些还表现出致癌活性。PAHs以含有两个及以上苯环的一系列化学结构为特征,根据它们的来源,可以通过氧化、氮化和烷基化表现出多种侧链修饰。[目的]讨论当代分析方法日益增加的能力,其不仅可以分辨PAHs中不同的化学结构,而且可以识别它们在环境介质中的浓度。本文以深水地平线事故后海产品污染为例,确定由于个别PAHs的分析灵敏度增加而在PAHs风险评估过程中出现的一些问题,并描述其中许多化合物的毒理学文献缺乏的现状。[讨论]PAHs,包括种类繁多的经化学修饰或取代的PAHs,是自然产生的,如果人群暴露于有害水平就可能会遭受健康风险。然而,目前的毒性评估并没有跟上现代分析方法及其对于被替代的PAHs不断增加的检测能力。因此,尽管我们可以在海产品和其他媒介中检测这些化合物,但并没有足够的关于这些化合物的潜在毒性信息,无法将它们用于人类健康风险评估和特征描述。[结论]今后的研究工作应该尝试从战略上填补这一毒理学知识欠缺,从而更好地进行环境介质或食物中关于PAHs的人体健康风险评估。这对于石油泄漏之后的影响尤为重要。 | Jeffrey Wickliffe Edward Overton Scott Frickel Jessi Howard Mark Wilson Bridget Simon Stephen Echsner Daniel Nguyen David Gauthe Diane Blake Charles Miller Cornelis Elferink Shakeel Ansari Harshica Ferno Edward Trapido Andrew Kane 张晶 汪源 金泰廙 | 2014 | 环境与职业医学2014，31，6： | 1 |
| 16 | Protein deep sequencing applied to biobank samples from patients with pancreatic cancer显示文摘 | Daniel Ansari Roland Andersson Monika P. Bauden Bodil Andersson Joanne B. Connolly Charlotte Welinder Agata Sasor Gy?rgy Marko-Varga | 2015 | Journal of Cancer Research and Clinical Oncology2015，，2： | 1 |
| 17 | Pancreaticoduodenectomy – the transition from a low- to a high-volume center显示文摘 | Daniel Ansari Caroline Williamsson Bobby Tingstedt Bodil Andersson Gert Lindell Roland Andersson | 2014 | Scandinavian Journal of Gastroenterology2014，，4： | 1 |
| 18 | Comparison of MUC4 expression in primary pancreatic cancer and paired lymph node metastases显示文摘 | Daniel Ansari Carlos Urey Chinmay Gundewar Monika Posaric Bauden Roland Andersson | 2013 | Scandinavian Journal of Gastroenterology2013，，10： | 1 |
| 19 | Pancreatic cancer screening in high-risk individuals with genetic susceptibility显示文摘Pancreatic cancer is still associated with a dismal prognosis,sometimes with a 5-year survival reported up to 10%,but the true figure is probably about 5%(1).Major breakthroughs in outcomes are lacking.One avenue for improving is survival is by earlier tumor detection,thereby increasing the proportion of patients that can undergo curative-intent surgery and concomitant chemotherapy.In recent years,optimistic outcomes have been reported for localized-stage disease,with 5-year survival rates of up to 44%(2). | Roland Andersson Daniel Ansari | 2023 | Hepatobiliary Surgery and Nutrition2023，12，4： | 0 |
| 20 | 去甲肾上腺素激活星形胶质细胞内核膜上的β1-肾上腺素能受体显示文摘去甲肾上腺素对星形胶质细胞的代谢、神经保护和免疫调节功能有强大的影响。直到最近,去甲肾上腺素的所有作用尚被认为是由仅存在于细胞质膜的受体介导的。然而,最近对心肌细胞的研究已经确定定位于细胞内膜(包括高尔基体和内核膜)的肾上腺素能受体,并表明去甲肾上腺素可以通过转运蛋白介导的摄取而作用于这些受体。我们最近发现了一种高容量去甲肾上腺素转运蛋白有机阳离子转运蛋白3(OCT3)。该转运蛋白密集定位于星形胶质细胞的外核膜,这表明肾上腺素能信号传导也可能发生在这些细胞的内核膜上。本研究证实:使用免疫荧光和蛋白质印迹技术显示β1-肾上腺素受体定位于星形胶质细胞内核膜;关键的肾上腺素能信号通路组分存在于星形胶质细胞核中;且OCT3和其他儿茶酚胺转运蛋白于星形胶质细胞质膜和核膜均表达。为了测试核膜β1-肾上腺素能受体的功能,我们使用荧光生物传感器实时监测星形胶质细胞核中的蛋白激酶A(PKA)活性。用去甲肾上腺素处理星形胶质细胞会导致核区室中PKA活性的快速增加。用儿茶酚胺摄取抑制剂预处理星形胶质细胞可阻断去甲肾上腺素诱导的核PKA活性的快速增加。这些研究首次记录了任何中枢神经系统细胞核膜上的功能性肾上腺素能受体,揭示了去甲肾上腺素可能直接影响核过程的新机制。这种机制可能与先前描述的去甲肾上腺素的神经保护、代谢和免疫调节作用有关。 | Kelsey C Benton Daniel S Wheeler Beliz Kurtoglu Mahshid Bagher Zadeh Ansari Daniel P Cibich Dante A Gonzalez Matthew R Herbst Saema Khursheed Rachel C Knorr Doug Lobner Jenree G Maglasang Kayla E Rohr Analisa Taylor Robert C Twining Paul JWitt Paul J Gasser 杜一星(编译) | 2022 | 神经损伤与功能重建2022，17，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员